

**National Institute for Health and Care Excellence
Medical Technologies Evaluation Programme**

**MT196 – The geko device for reducing the risk of venous thromboembolism
Consultation Comments table for MTCD2**

MTAC date: 10 April 2014

There were 7 consultation comments from 3 consultees (1 manufacturer, 1 representative of AntiCoagulation Europe and 1 from the Department of Health). The comments are reproduced in full.

Co m. no.	Consultee number and organisation	Sec. no.	Comments	Response
1	1.ACE	1	ACE agrees with the provisional recommendations as the device provides a valuable alternative to managing risk of VTE in high risk patients who may not be eligible for other forms of prophylaxis	Thank you for your comment.
2	1.ACE	2	The device will complement existing mechanical prophylaxis options extending protection to those who would otherwise be at heightened risk as identified. We note that recommendation is timely in respect of inclusion in the updated NICE CG 92	Thank you for your comment.
3	1.ACE	3	ACE agrees with recommendations with regard to further research and data collection to expand its use in broader population and potential comparator to other mechanical methods currently available. How will the manufacturer respond to the recommendation to encourage research and data collection for this purpose? Potentially, this device could have a significant impact on people in terms of safety, convenience and efficacy if available for	Thank you for your comment.

MT196 – The geko device for reducing the risk of venous thromboembolism

Co m. no.	Consultee number and organisation	Sec. no.	Comments	Response
			sole use unlike pneumatic devices which are shared between patients and require the patient to be de-mobilised whilst attached.	
4	1.ACE	4	Agree -continuance after discharge could be beneficial to people and agree that costs and benefits of this should be evaluated. Simplicity of application of the device by individual or carer should be minimal	Thank you for your comment.
5	1.ACE	6	Further research will hopefully provide evidence that the device can be utilised in a broader population of 'at risk' patients who otherwise may not be able to use current mechanical methods. Reducing VTE paramount to well-being of patients, family and carers and with risk reduced, lessen burden on NHS for re-admissions and treatment	Thank you for your comment.
6	2.Sponsor	General	The Sponsor would like to thank the Committee for this consultation document and would like to record that it has no further comment to make at this stage of the process.	Thank you for your comment.
7	3. Department of Health	General	<p>Thank you for the opportunity to comment on the evaluation documents for the above medical technology.</p> <p>I wish to confirm that the Department of Health has no substantive comments to make, regarding this consultation.</p>	Thank you for your comment.

MT196 – The geko device for reducing the risk of venous thromboembolism

"Comments received in the course of consultations carried out by NICE are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the submissions that NICE has received, and are not endorsed by NICE, its officers or Advisory committees."